VERTEX PHARMACEUTICALS INC / MA Goodwill & Intangibles Disclosure
As of December 31, 2025 | As of December 31, 2024 | ||||||||||||
Estimated Useful lives | Gross Carrying Amount | Accumulated Amortization | Net Carrying Amount | Gross Carrying Amount | Accumulated Amortization | Net Carrying Amount | |||||||
(in millions, except useful lives) | |||||||||||||
In-process research and development | Indefinite | $224.6 | $— | $224.6 | $603.6 | $— | $603.6 | ||||||
Finite-lived intangible assets - marketed products | 10 to 12 years | 238.0 | (42.1) | 195.9 | 238.0 | (21.9) | 216.1 | ||||||
Finite-lived intangible assets - assembled workforce | 3 years | 7.7 | (4.0) | 3.7 | 7.7 | (1.5) | $6.2 | ||||||
Total other intangible assets, net | $470.3 | $(46.1) | $424.2 | $849.3 | $(23.4) | $825.9 | |||||||
Year | Estimated Amortization Expense | |
(in millions) | ||
2026 | $22.7 | |
2027 | $21.3 | |
2028 | $20.2 | |
2029 | $20.2 | |
2030 | $20.2 |
Want the next VERTEX PHARMACEUTICALS INC / MA goodwill & intangibles disclosure the moment it drops?
Set a Sentinel and we'll alert you the moment VERTEX PHARMACEUTICALS INC / MA's next filing hits EDGAR. No credit card, your email never gets sold.
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Feb 13, 2026 | Showing above |
| 2024 | Feb 13, 2025 | |
| 2023 | Feb 15, 2024 | |
| 2022 | Feb 10, 2023 | |
| 2021 | Feb 9, 2022 | |
| 2020 | Feb 11, 2021 | |
| 2019 | Feb 13, 2020 | |
| 2018 | Feb 13, 2019 | |
| 2017 | Feb 15, 2018 | |
| 2016 | Feb 23, 2017 | |
| 2015 | Feb 16, 2016 | |
About Goodwill & Intangibles Disclosures
Goodwill and intangible asset disclosures reveal the premium paid in acquisitions and how management assesses whether that premium retains its value. Since goodwill is no longer amortized under US GAAP, the annual impairment test is the only mechanism that adjusts carrying values downward — making the assumptions behind that test critically important for investors.
Key signals: a history of goodwill impairments suggests management consistently overpays for acquisitions. Watch the gap between reporting unit fair value and carrying amount — when fair value exceeds carrying amount by less than 10-20%, a small decline in business performance could trigger a write-down. For finite-lived intangibles, examine useful life assumptions across customer relationships, technology, and trade names; aggressive estimates inflate near-term earnings. Compare total intangibles-to-total-assets ratios against peers to assess acquisition dependency. Rising goodwill as a percentage of equity can signal balance sheet fragility.